The latest price target for Lantern Pharma (NASDAQ:LTRN) was reported by HC Wainwright & Co. on April 25, 2024. The analyst firm set a price target for $0.00 expecting LTRN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Lantern Pharma (NASDAQ:LTRN) was provided by HC Wainwright & Co., and Lantern Pharma reiterated their neutral rating.

There is no last upgrade for Lantern Pharma

There is no last downgrade for Lantern Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lantern Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lantern Pharma was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.

While ratings are subjective and will change, the latest Lantern Pharma (LTRN) rating was a reiterated with a price target of $0.00 to $0.00. The current price Lantern Pharma (LTRN) is trading at is $3.67, which is out of the analyst’s predicted range.